Price$5.36+0.24 (+4.59%)
01:30 PM07:45 PM
News · 26 weeks58+60%
2026-01-182026-07-12
Mix2990d
- Insider14(48%)
- SEC Filings8(28%)
- Other4(14%)
- Earnings2(7%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Medical Officer Podnos Yale exercised 23,452 shares at a strike of $1.90 and sold $150,340 worth of shares (23,452 units at $6.41) (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERLarge owner Chernett Jorey bought $87,750 worth of shares (15,000 units at $5.85), increasing direct ownership by 0.14% to 10,630,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Tzoumakas Kimberly Jo was granted 17,185 shares (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Stolper Mark was granted 25,833 shares (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oncology Institute, Inc. (0001799191) (Filer)
- PRThe Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving LiquidityCERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed. This transaction is intended to increase liquidity, improve operating flexibility and extend debt maturities. Under the new financing arrangements with OrbiMed, TOI repaid the outstanding balance of its $86 million senior secured convertible note with a new $75 million term loan with OrbiMed maturing in 2031 as well as approximately $11 mi
- ANALYSTLake Street initiated coverage on The Oncology Institute with a new price targetLake Street initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $10.00
- INSIDERLarge owner Chernett Jorey bought $90,360 worth of shares (18,000 units at $5.02), increasing direct ownership by 0.17% to 10,615,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Oncology Institute, Inc. (0001799191) (Filer)
- INSIDERChief Medical Officer Podnos Yale sold $126,094 worth of shares (23,451 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 259,527 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECSEC Form 144 filed by The Oncology Institute Inc.144 - Oncology Institute, Inc. (0001799191) (Subject)
- INSIDERLarge owner Chernett Jorey bought $57,000 worth of shares (12,000 units at $4.75), increasing direct ownership by 0.11% to 10,579,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- PRThe Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring ConferenceCERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D. Podnos, MD, MPH, FACS, Chief Medical Officer, will participate in a panel discussion at the APG Spring Conference on May 28, 2026, in San Diego. The session, "Engaging More Specialists in Value-Based Care," will bring together healthcare leaders to discuss the growing role of specialists in advancing value-based care. "Specialists play a critical role in delivering high-quality, coordinated care while helping improve outcomes and reduce the total cost of care," said Dr. Podnos. "As oncology c
- INSIDERChief Medical Officer Podnos Yale disposed of $8,068 worth of shares (1,805 units at $4.47), decreasing direct ownership by 0.63% to 282,978 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERChief Executive Officer Virnich Daniel disposed of $103,069 worth of shares (23,058 units at $4.47), decreasing direct ownership by 0.98% to 2,337,166 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERChief Financial Officer Carter Robert Ross disposed of $7,170 worth of shares (1,604 units at $4.47), decreasing direct ownership by 0.39% to 414,801 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Oncology Institute, Inc. (0001799191) (Filer)
- INSIDERLarge owner Chernett Jorey bought $156,595 worth of shares (38,500 units at $4.07), increasing direct ownership by 0.37% to 10,567,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERLarge owner Chernett Jorey bought $122,700 worth of shares (30,000 units at $4.09), increasing direct ownership by 0.29% to 10,529,358 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by The Oncology Institute Inc.SCHEDULE 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
- PRThe Oncology Institute to Participate in B. Riley Securities Institutional Investor ConferenceCERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the B. Riley Securities Institutional Investor Conference, being held in Marina Del Rey, CA on Thursday, May 21, 2026, including a fireside chat from 9:00–9:40 a.m. PT. A webcast link of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.theoncologyinstitute.com/. ____________________________ About The Oncology Institute (www.theonco
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Oncology Institute, Inc. (0001799191) (Filer)
- SECSEC Form 10-Q filed by The Oncology Institute Inc.10-Q - Oncology Institute, Inc. (0001799191) (Filer)
- PRThe Oncology Institute Reports First Quarter 2026 Financial ResultsCERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026. Recent Operational Highlights Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 78% in the quarter as compared to prior year same quarter, reflecting the volume growth across our membership and continued attachment rate improvements.Contract expansion bringing our total Medicare Advantage lives to 200,000 across 25 counties in Florida effective July 1, 2026. Preparing to launch our propr
- SECSEC Form DEFA14A filed by The Oncology Institute Inc.DEFA14A - Oncology Institute, Inc. (0001799191) (Filer)
TOI FAQ
7 questionsWhat does The Oncology Institute Inc. do?
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in...Where does TOI stock trade?
The Oncology Institute Inc. (TOI) is listed on NASDAQ.What sector and industry is TOI in?
The Oncology Institute Inc. operates in the Health Care sector, Medical/Nursing Services industry.When did The Oncology Institute Inc. go public?
The Oncology Institute Inc. (TOI) completed its IPO in 2020.What are analysts saying about TOI?
The Oncology Institute Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1000.00 price target on 2026-07-06. Recent price targets range from $250.00 to $1000.00.What companies are similar to TOI?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), HIMS (Hims & Hers Health Inc.), CHE (Chemed Corp), LFST (LifeStance Health Group Inc.), AMED (Amedisys Inc). Compare TOI side-by-side with any of them on Quantisnow.How can I track TOI on Quantisnow?
Quantisnow aggregates The Oncology Institute Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TOI to receive live email and push alerts on every new disclosure.